DAPT using cilostazol more effective, safer option in recurrent ischemic stroke: Study

A group of researchers from China examined and clarified the effectiveness and safety of each combination.

In the CSPS.com trial, a multicenter, open-label, randomized controlled study, patients with high-risk, non-cardioembolic ischemic stroke 8 to 180 days after onset treated with aspirin or clopidogrel alone at the discretion of the physician in charge were recruited. Patients were randomly assigned to receive either monotherapy or DAPT using cilostazol and followed for 0.5 to 3.5 years. The primary efficacy outcome was the first recurrence of ischemic stroke. The safety outcome was severe or life-threatening bleeding. The analysis was based on the underlying antiplatelet agents.

The results of the study are as follows:

• A total of 763 patients taking aspirin and 1116 taking, clopidogrel was included in the intention-to-treat analysis.
• Although the clopidogrel group had more risk factors than the aspirin group, the primary efficacy outcome and safety outcome did not differ significantly between the 2 groups.
• In the aspirin group, the primary efficacy outcome and safety outcome did not differ significantly between the DAPT group and the aspirin-monotherapy group.
• In the clopidogrel group, the primary endpoint occurred at a rate of 2.31 per 100 patient-years in the DAPT group and 5.19 per 100 patient-years in the clopidogrel-monotherapy group.
• Safety outcome did not differ significantly between groups.

Thus, the researchers concluded that the combination of cilostazol and clopidogrel significantly reduced the recurrence of ischemic stroke without increasing the bleeding risk in non-cardioembolic, high-risk patients.

Reference:

Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial by Hoshino H et. al published in the Stroke- AHA journal.

https://doi.org/10.1161/STROKEAHA.121.034378